Current antiretroviral therapy: An overview

Quality of Life Research

Volumn 6, Issue 6, 1997, Pages 471-474

  Gulick, Roy M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Protease inhibitors; Quality of life

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRAMMUNE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DIARRHEA; ENZYME ACTIVITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LEUKOPENIA; LIFESTYLE; NAUSEA; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0030753305     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018447829842     Document Type: Conference Paper

References (31)

1. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficency virus type 1 infection. Nature 1995; 373:117-122.
2. Ho DD, Neumann AU, Perelson AS et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
3. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450-451 (editorial).
4. Saag MS, Holodniy M, Kurtizkes DR et al. HIV viral load markers in clinical practice. Nature Med 1996; 2: 625-629.
5. Mellors JW, Rinaldo CR, Jr, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
6. Katzenstein DA, Hammer SM, Hughes MD et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millilitre. N Engl J Med 1996; 335: 1091-1098.
7. Fischl MA, Richmann DD, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-191.
8. Concorde Coordinating Committee. Concorde: MRC/ ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
9. Volberding PA, Lagakos SW, Grimes JM et al. A comparison of immediate with deferred zidovudine therapy for symptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimetre. N Engl J Med 1995; 333: 401-407.
10. Larder BA, Kemp SD. Multiple mutations in HIV-reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-1158.
11. Dolin R, Amato D, Fischl M et al. Zidovudine compared to didanosine in patients with advanced HIV infection and little or no previous experience with zidovudine. Arch Intent Med 1995; 155: 961-974.
12. AIDS Clinical Trial Group Executive Summary, ACTG 114. National Institute of Allergy and Infectious Diseases.
13. Kahn JO, Lagakos SW, Richman DD et al. A controlled study comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-587.
14. Spruance SL, Pavia AT, Mellors JW et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann Intern Med 1997; 126: 355-363.
15. Hammer SM, Katzenstein DA, Hughes MD et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millilitre. N Engl J Med 1996; 335: 1081-1090.
16. The Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing the combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
17. Saravolatz LD, Winslow DL, Collins G et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimetre. N Engl J Med 1996; 335: 1099-1106.
18. Eron JJ, Benoit SL, Jemesk J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimetre. N Engl J Med 1995; 333: 1662-1669.
19. Bartlett JA, Benoit SL, Johnson VA et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 161-172.
20. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-1421.
21. 3 In: Abstracts of the 11th International Conference on AIDS, Vancouver, BC., July 7-12, 1996: 22 (abstract).
22. Henry K, Tierney C, Kahn J et al. A randomized, double-blind, placebo-controlled study comparing combination nucleoside and triple therapy for the treatment of advanced HIV disease. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997: LB6 (abstract).
23. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors-a review for clinicians. JAMA 1997; 277: 145-153.
24. Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-1533.
25. 3. In: Abstracts of the 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995: I172 (abstract).
26. Condra JH, Schleif WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-571.
27. Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011-1017.
28. Cameron B, Heath-Chiozzi M, Kravcik S et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Abstracts of the Third Conference on Retroviruses and Opportunistic Infections, Washington DC, Jan. 28-Feb. 1, 1996: LB6a (abstract).
29. Gulick R, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral use. N Engl J Med 1997 (in press).
30. Powderly W, Sension M, Conant M et al. The efficacy of Viracept in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22-26, 1997; 370 (abstract).
31. Hammer SM, Squires KE, Hughes MD, et al. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogs in human immunodeficiency virus infected persons with CD4 cell counts less than or equal to 200 per cubic millimeter. N Engl J Med 1997; (in press).